Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 14/20 | 0.54 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | KYNU | Q16719 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12232414 | 1.00 | CASP1 (0.54) | CASP1MMP9SLC15A1ALDH1A1ALOX15 | |
| SCHEMBL19364747 | 0.90 | CASP1 (0.52) | CASP1MMP9SLC15A1ALDH1A1ALOX15 | |
| SCHEMBL21057596 | 0.88 | CASP1 (0.59) | CASP1CTSK | |
| SCHEMBL755795 | 0.88 | MMP9 (0.52) | CASP1MMP9SLC15A1ALDH1A1ALOX15 | |
| SCHEMBL25491977 | 0.88 | MMP9 (0.52) | CASP1MMP9ALDH1A1ALOX15KYNU | |
| SCHEMBL15996601 | 0.86 | ALDH1A1 (0.55) | CASP1MMP9SLC15A1ALDH1A1ALOX15 | |
| SCHEMBL890103 | 0.86 | ALDH1A1 (0.55) | CASP1MMP9SLC15A1ALDH1A1ALOX15 | |
| SCHEMBL8906664 | 0.84 | MMP9 (0.52) | CASP1MMP9SLC15A1ALDH1A1ALOX15 | |
| SCHEMBL21057770 | 0.84 | CASP1 (0.69) | CASP1 | |
| SCHEMBL13132237 | 0.83 | KLK7 (0.49) | CASP1MMP9ALDH1A1ALOX15KYNU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8211928-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-07-03 | — | — | US | disclosed |
| US-8143414-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110130433-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-06-02 | — | — | US | disclosed |
| US-20110098327-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-28 | — | — | US | disclosed |
| US-20100249190-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249190-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | CASP1 3668/4885MMP9 4471/4885SLC15A1 3581/4885 |
| US-20110130433-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | CASP1 3668/4885MMP9 4471/4885SLC15A1 3581/4885 |
| US-20110098327-A1 | Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | CASP1 3824/4885MMP9 4419/4885SLC15A1 3713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.